Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients taking are still taking cheaper weight-loss alternatives.
An article from
Obesity drugs
Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
Published July 17, 2026
By
Compounded GLP-1 weight-loss ads are flooding social media without FDA oversight or safety warnings — putting patients,…
Americans are chasing cheaper GLP-1 sources but legal and health risks abound.
Demand for compounded GLP-1 drugs persists despite shortage resolutions
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.
Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they…
A new Gallup poll found about 11% of Americans were taking a GLP-1 medication for weight loss.
